These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23012630)

  • 1. Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway.
    Zuo J; Rowe M
    Viruses; 2012 Aug; 4(8):1335-53. PubMed ID: 23012630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpesviruses and immunity: the art of evasion.
    Griffin BD; Verweij MC; Wiertz EJ
    Vet Microbiol; 2010 Jun; 143(1):89-100. PubMed ID: 20303681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
    Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
    J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.
    Zuo J; Hislop AD; Leung CS; Sabbah S; Rowe M
    J Virol; 2013 May; 87(10):5340-50. PubMed ID: 23449805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus.
    Johnson DC; Hegde NR
    Curr Top Microbiol Immunol; 2002; 269():101-15. PubMed ID: 12224504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls.
    Horst D; Ressing ME; Wiertz EJ
    Immunol Cell Biol; 2011 Mar; 89(3):359-66. PubMed ID: 21301483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of interference with the MHC class I-restricted pathway of antigen presentation by herpesviruses.
    Hill AB
    Immunol Cell Biol; 1996 Dec; 74(6):523-6. PubMed ID: 8989590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
    Neumann J; Eis-Hübinger AM; Koch N
    J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
    Hegde NR; Tomazin RA; Wisner TW; Dunn C; Boname JM; Lewinsohn DM; Johnson DC
    J Virol; 2002 Nov; 76(21):10929-41. PubMed ID: 12368336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MHC class I antigen presentation pathway: strategies for viral immune evasion.
    Hewitt EW
    Immunology; 2003 Oct; 110(2):163-9. PubMed ID: 14511229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune evasion during varicella zoster virus infection of keratinocytes.
    Black AP; Jones L; Malavige GN; Ogg GS
    Clin Exp Dermatol; 2009 Dec; 34(8):e941-4. PubMed ID: 19549245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equine herpesvirus type 4 UL56 and UL49.5 proteins downregulate cell surface major histocompatibility complex class I expression independently of each other.
    Said A; Azab W; Damiani A; Osterrieder N
    J Virol; 2012 Aug; 86(15):8059-71. PubMed ID: 22623773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The herpesvirus stealth program.
    Huang T; Osterrieder N
    Oncotarget; 2015 Sep; 6(26):21761-2. PubMed ID: 26335280
    [No Abstract]   [Full Text] [Related]  

  • 14. Human Cytomegalovirus Decreases Major Histocompatibility Complex Class II by Regulating Class II Transactivator Transcript Levels in a Myeloid Cell Line.
    Sandhu PK; Buchkovich NJ
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31915281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune escape of γ-herpesviruses from adaptive immunity.
    Hu Z; Usherwood EJ
    Rev Med Virol; 2014 Nov; 24(6):365-78. PubMed ID: 24733560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parasite Manipulation of the Invariant Chain and the Peptide Editor H2-DM Affects Major Histocompatibility Complex Class II Antigen Presentation during Toxoplasma gondii Infection.
    Leroux LP; Nishi M; El-Hage S; Fox BA; Bzik DJ; Dzierszinski FS
    Infect Immun; 2015 Oct; 83(10):3865-80. PubMed ID: 26195549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.
    Zuo J; Thomas WA; Haigh TA; Fitzsimmons L; Long HM; Hislop AD; Taylor GS; Rowe M
    PLoS Pathog; 2011 Dec; 7(12):e1002455. PubMed ID: 22216005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD4
    Lawler C; Stevenson PG
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.